Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 214

1.

Metastatic Heterogeneity of Breast Cancer: Companion and Theranostic Approach in Nuclear Medicine.

Montemagno C, Pagès G.

Cancers (Basel). 2020 Mar 29;12(4). pii: E821. doi: 10.3390/cancers12040821. Review.

2.

Identification of a new aggressive axis driven by ciliogenesis and absence of VDAC1-ΔC in clear cell Renal Cell Carcinoma patients.

Fabbri L, Dufies M, Lacas-Gervais S, Gardie B, Gad-Lapiteau S, Parola J, Nottet N, Meyenberg Cunha de Padua M, Contenti J, Borchiellini D, Ferrero JM, Leclercq NR, Ambrosetti D, Mograbi B, Richard S, Viotti J, Chamorey E, Sadaghianloo N, Rouleau M, Craigen WJ, Mari B, Clavel S, Pagès G, Pouysségur J, Bost F, Mazure NM.

Theranostics. 2020 Feb 3;10(6):2696-2713. doi: 10.7150/thno.41001. eCollection 2020.

3.

Depicting the genetic architecture of pediatric cancers through an integrative gene network approach.

Savary C, Kim A, Lespagnol A, Gandemer V, Pellier I, Andrieu C, Pagès G, Galibert MD, Blum Y, de Tayrac M.

Sci Rep. 2020 Jan 27;10(1):1224. doi: 10.1038/s41598-020-58179-0.

4.

Assessment of chemical-crosslink-assisted protein structure modeling in CASP13.

Fajardo JE, Shrestha R, Gil N, Belsom A, Crivelli SN, Czaplewski C, Fidelis K, Grudinin S, Karasikov M, Karczyńska AS, Kryshtafovych A, Leitner A, Liwo A, Lubecka EA, Monastyrskyy B, Pagès G, Rappsilber J, Sieradzan AK, Sikorska C, Trabjerg E, Fiser A.

Proteins. 2020 Mar;88(3):540. doi: 10.1002/prot.25867. Epub 2020 Jan 3. No abstract available.

PMID:
31977133
5.

The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor.

Grépin R, Guyot M, Dumond A, Durivault J, Ambrosetti D, Roussel JF, Dupré F, Quintens H, Pagès G.

Theranostics. 2020 Jan 1;10(3):1107-1121. doi: 10.7150/thno.38346. eCollection 2020.

6.

Synthesis, 3D-structure and stability analyses of NRPa-308, a new promising anti-cancer agent.

Brachet E, Dumond A, Liu WQ, Fabre M, Selkti M, Raynaud F, Hermine O, Benhida R, Belmont P, Garbay C, Lepelletier Y, Ronco C, Pagès G, Demange L.

Bioorg Med Chem Lett. 2019 Dec 15;29(24):126710. doi: 10.1016/j.bmcl.2019.126710. Epub 2019 Oct 16.

PMID:
31699610
7.

99mTc-A1 as a Novel Imaging Agent Targeting Mesothelin-Expressing Pancreatic Ductal Adenocarcinoma.

Montemagno C, Cassim S, Trichanh D, Savary C, Pouyssegur J, Pagès G, Fagret D, Broisat A, Ghezzi C.

Cancers (Basel). 2019 Oct 10;11(10). pii: E1531. doi: 10.3390/cancers11101531.

8.

Blind prediction of homo- and hetero-protein complexes: The CASP13-CAPRI experiment.

Lensink MF, Brysbaert G, Nadzirin N, Velankar S, Chaleil RAG, Gerguri T, Bates PA, Laine E, Carbone A, Grudinin S, Kong R, Liu RR, Xu XM, Shi H, Chang S, Eisenstein M, Karczynska A, Czaplewski C, Lubecka E, Lipska A, Krupa P, Mozolewska M, Golon Ł, Samsonov S, Liwo A, Crivelli S, Pagès G, Karasikov M, Kadukova M, Yan Y, Huang SY, Rosell M, Rodríguez-Lumbreras LA, Romero-Durana M, Díaz-Bueno L, Fernandez-Recio J, Christoffer C, Terashi G, Shin WH, Aderinwale T, Maddhuri Venkata Subraman SR, Kihara D, Kozakov D, Vajda S, Porter K, Padhorny D, Desta I, Beglov D, Ignatov M, Kotelnikov S, Moal IH, Ritchie DW, Chauvot de Beauchêne I, Maigret B, Devignes MD, Ruiz Echartea ME, Barradas-Bautista D, Cao Z, Cavallo L, Oliva R, Cao Y, Shen Y, Baek M, Park T, Woo H, Seok C, Braitbard M, Bitton L, Scheidman-Duhovny D, Dapkūnas J, Olechnovič K, Venclovas Č, Kundrotas PJ, Belkin S, Chakravarty D, Badal VD, Vakser IA, Vreven T, Vangaveti S, Borrman T, Weng Z, Guest JD, Gowthaman R, Pierce BG, Xu X, Duan R, Qiu L, Hou J, Ryan Merideth B, Ma Z, Cheng J, Zou X, Koukos PI, Roel-Touris J, Ambrosetti F, Geng C, Schaarschmidt J, Trellet ME, Melquiond ASJ, Xue L, Jiménez-García B, van Noort CW, Honorato RV, Bonvin AMJJ, Wodak SJ.

Proteins. 2019 Dec;87(12):1200-1221. doi: 10.1002/prot.25838. Epub 2019 Oct 25.

PMID:
31612567
9.

Assessment of chemical-crosslink-assisted protein structure modeling in CASP13.

Fajardo JE, Shrestha R, Gil N, Belsom A, Crivelli SN, Czaplewski C, Fidelis K, Grudinin S, Karasikov M, Karczyńska AS, Kryshtafovych A, Leitner A, Liwo A, Lubecka EA, Monastyrskyy B, Pagès G, Rappsilber J, Sieradzan AK, Sikorska C, Trabjerg E, Fiser A.

Proteins. 2019 Dec;87(12):1283-1297. doi: 10.1002/prot.25816. Epub 2019 Oct 7. Erratum in: Proteins. 2020 Mar;88(3):540.

PMID:
31569265
10.

Antioxidant and Cardioprotective Effects of EPA on Early Low-Severity Sepsis through UCP3 and SIRT3 Upholding of the Mitochondrial Redox Potential.

Leger T, Azarnoush K, Traoré A, Cassagnes L, Rigaudière JP, Jouve C, Pagès G, Bouvier D, Sapin V, Pereira B, Bonny JM, Demaison L.

Oxid Med Cell Longev. 2019 Aug 26;2019:9710352. doi: 10.1155/2019/9710352. eCollection 2019.

11.

Intrathecal AAVrh10 corrects biochemical and histological hallmarks of mucopolysaccharidosis VII mice and improves behavior and survival.

Pagès G, Giménez-Llort L, García-Lareu B, Ariza L, Navarro M, Casas C, Chillón M, Bosch A.

Hum Mol Genet. 2019 Nov 1;28(21):3610-3624. doi: 10.1093/hmg/ddz220.

PMID:
31511867
12.

New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments.

Dufies M, Grytsai O, Ronco C, Camara O, Ambrosetti D, Hagege A, Parola J, Mateo L, Ayrault M, Giuliano S, Grépin R, Lagarde N, Montes M, Auberger P, Demange L, Benhida R, Pagès G.

Theranostics. 2019 Jul 9;9(18):5332-5346. doi: 10.7150/thno.34681. eCollection 2019. Review.

13.

In Vivo Assessment of VCAM-1 Expression by SPECT/CT Imaging in Mice Models of Human Triple Negative Breast Cancer.

Montemagno C, Dumas L, Cavaillès P, Ahmadi M, Bacot S, Debiossat M, Soubies A, Djaïleb L, Leenhardt J, Leiris N, Dufies M, Pagès G, Hernot S, Devoogdt N, Perret P, Riou L, Fagret D, Ghezzi C, Broisat A.

Cancers (Basel). 2019 Jul 23;11(7). pii: E1039. doi: 10.3390/cancers11071039.

14.

DeepSymmetry: using 3D convolutional networks for identification of tandem repeats and internal symmetries in protein structures.

Pagès G, Grudinin S.

Bioinformatics. 2019 Dec 15;35(24):5113-5120. doi: 10.1093/bioinformatics/btz454.

PMID:
31161198
15.

Protein model quality assessment using 3D oriented convolutional neural networks.

Pagès G, Charmettant B, Grudinin S.

Bioinformatics. 2019 Sep 15;35(18):3313-3319. doi: 10.1093/bioinformatics/btz122.

PMID:
30874723
16.

Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5.

Giuliano S, Dufies M, Ndiaye PD, Viotti J, Borchiellini D, Parola J, Vial V, Cormerais Y, Ohanna M, Imbert V, Chamorey E, Rioux-Leclercq N, Savina A, Ferrero JM, Mograbi B, Pagès G.

Theranostics. 2019 Jan 30;9(4):1181-1199. doi: 10.7150/thno.29093. eCollection 2019.

17.

VEGFC acts as a double-edged sword in renal cell carcinoma aggressiveness.

Ndiaye PD, Dufies M, Giuliano S, Douguet L, Grépin R, Durivault J, Lenormand P, Glisse N, Mintcheva J, Vouret-Craviari V, Mograbi B, Wurmser M, Ambrosetti D, Rioux-Leclercq N, Maire P, Pagès G.

Theranostics. 2019 Jan 21;9(3):661-675. doi: 10.7150/thno.27794. eCollection 2019.

18.

Inhibition of the amino-acid transporter LAT1 demonstrates anti-neoplastic activity in medulloblastoma.

Cormerais Y, Pagnuzzi-Boncompagni M, Schrötter S, Giuliano S, Tambutté E, Endou H, Wempe MF, Pagès G, Pouysségur J, Picco V.

J Cell Mol Med. 2019 Apr;23(4):2711-2718. doi: 10.1111/jcmm.14176. Epub 2019 Feb 19.

19.

[VEGF-C and lymphatic vessels: a double-edged sword in tumor development and metastasis].

Ndiaye PD, Pagès G.

Med Sci (Paris). 2019 Feb;35(2):132-137. doi: 10.1051/medsci/2019002. Epub 2019 Feb 18. Review. French.

20.

Smooth orientation-dependent scoring function for coarse-grained protein quality assessment.

Karasikov M, Pagès G, Grudinin S.

Bioinformatics. 2019 Aug 15;35(16):2801-2808. doi: 10.1093/bioinformatics/bty1037.

PMID:
30590384
21.

Glyoxalase activity in human erythrocytes and mouse lymphoma, liver and brain probed with hyperpolarized 13C-methylglyoxal.

Shishmarev D, Kuchel PW, Pagès G, Wright AJ, Hesketh RL, Kreis F, Brindle KM.

Commun Biol. 2018 Dec 21;1:232. doi: 10.1038/s42003-018-0241-1. eCollection 2018.

22.

Correction: The path to « the Golden Age » for the treatment of metastatic renal cell carcinoma.

Pagès G.

Oncotarget. 2018 Nov 6;9(87):35796. doi: 10.18632/oncotarget.26340. eCollection 2018 Nov 6.

23.

Uncertainties of calculated Cramér-Rao lower bounds: implications for quantitative MRS.

Bonny JM, Pagès G.

Magn Reson Med. 2019 Feb;81(2):759-764. doi: 10.1002/mrm.27415. Epub 2018 Sep 11.

PMID:
30203860
24.

The path to « the Golden Age » for the treatment of metastatic renal cell carcinoma.

Pagès G.

Oncotarget. 2018 Aug 3;9(60):31564-31565. doi: 10.18632/oncotarget.25832. eCollection 2018 Aug 3. No abstract available. Erratum in: Oncotarget. 2018 Nov 6;9(87):35796.

25.

Analytical symmetry detection in protein assemblies. II. Dihedral and cubic symmetries.

Pagès G, Grudinin S.

J Struct Biol. 2018 Sep;203(3):185-194. doi: 10.1016/j.jsb.2018.05.005. Epub 2018 Jun 15.

PMID:
29902523
26.

Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma.

Dufies M, Nollet M, Ambrosetti D, Traboulsi W, Viotti J, Borchiellini D, Grépin R, Parola J, Giuliano S, Helley-Russick D, Bensalah K, Ravaud A, Bernhard JC, Schiappa R, Bardin N, Dignat-George F, Rioux-Leclercq N, Oudard S, Négrier S, Ferrero JM, Chamorey E, Blot-Chabaud M, Pagès G.

Theranostics. 2018 Mar 28;8(9):2447-2458. doi: 10.7150/thno.23002. eCollection 2018.

27.

Analytical symmetry detection in protein assemblies. I. Cyclic symmetries.

Pagès G, Kinzina E, Grudinin S.

J Struct Biol. 2018 Aug;203(2):142-148. doi: 10.1016/j.jsb.2018.04.004. Epub 2018 Apr 27.

PMID:
29705493
28.

The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma.

Polena H, Creuzet J, Dufies M, Sidibé A, Khalil-Mgharbel A, Salomon A, Deroux A, Quesada JL, Roelants C, Filhol O, Cochet C, Blanc E, Ferlay-Segura C, Borchiellini D, Ferrero JM, Escudier B, Négrier S, Pages G, Vilgrain I.

Br J Cancer. 2018 May;118(9):1179-1188. doi: 10.1038/s41416-018-0054-5. Epub 2018 Mar 22.

29.

ATP-competitive Plk1 inhibitors induce caspase 3-mediated Plk1 cleavage and activation in hematopoietic cell lines.

Dufies M, Ambrosetti D, Boulakirba S, Calleja A, Savy C, Furstoss N, Zerhouni M, Parola J, Aira-Diaz L, Marchetti S, Orange F, Lacas-Gervais S, Luciano F, Jacquel A, Robert G, Pagès G, Auberger P.

Oncotarget. 2017 Dec 23;9(13):10920-10933. doi: 10.18632/oncotarget.23650. eCollection 2018 Feb 16.

30.

AKT1 restricts the invasive capacity of head and neck carcinoma cells harboring a constitutively active PI3 kinase activity.

Brolih S, Parks SK, Vial V, Durivault J, Mostosi L, Pouysségur J, Pagès G, Picco V.

BMC Cancer. 2018 Mar 5;18(1):249. doi: 10.1186/s12885-018-4169-0.

31.

The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma.

Ambrosetti D, Dufies M, Dadone B, Durand M, Borchiellini D, Amiel J, Pouyssegur J, Rioux-Leclercq N, Pages G, Burel-Vandenbos F, Mazure NM.

PLoS One. 2018 Feb 26;13(2):e0193477. doi: 10.1371/journal.pone.0193477. eCollection 2018.

32.

Structural and functional analysis of coral Hypoxia Inducible Factor.

Zoccola D, Morain J, Pagès G, Caminiti-Segonds N, Giuliano S, Tambutté S, Allemand D.

PLoS One. 2017 Nov 8;12(11):e0186262. doi: 10.1371/journal.pone.0186262. eCollection 2017.

33.

NRPa-308, a new neuropilin-1 antagonist, exerts in vitro anti-angiogenic and anti-proliferative effects and in vivo anti-cancer effects in a mouse xenograft model.

Liu WQ, Lepelletier Y, Montès M, Borriello L, Jarray R, Grépin R, Leforban B, Loukaci A, Benhida R, Hermine O, Dufour S, Pagès G, Garbay C, Raynaud F, Hadj-Slimane R, Demange L.

Cancer Lett. 2018 Feb 1;414:88-98. doi: 10.1016/j.canlet.2017.10.039. Epub 2017 Oct 28.

PMID:
29111348
34.

Spontaneous chondroma formation in CD2-Cre-driven Erk-deficient mice.

Shiokawa M, Lu X, Miyake Y, Ishikawa E, Pagès G, Pouysségur J, Ogata M, Yamasaki S.

Int Immunol. 2017 Dec 18;29(10):479-485. doi: 10.1093/intimm/dxx056.

PMID:
29106539
35.

Pulsed-field gradient nuclear magnetic resonance measurements (PFG NMR) for diffusion ordered spectroscopy (DOSY) mapping.

Pagès G, Gilard V, Martino R, Malet-Martino M.

Analyst. 2017 Oct 9;142(20):3771-3796. doi: 10.1039/c7an01031a. Review.

PMID:
28858342
36.

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas.

Dufies M, Giuliano S, Viotti J, Borchiellini D, Cooley LS, Ambrosetti D, Guyot M, Ndiaye PD, Parola J, Claren A, Schiappa R, Gal J, Frangeul A, Jacquel A, Cassuto O, Grépin R, Auberger P, Bikfalvi A, Milano G, Escudier B, Rioux-Leclercq N, Porta C, Negrier S, Chamorey E, Ferrero JM, Pagès G.

Br J Cancer. 2017 Sep 26;117(7):947-953. doi: 10.1038/bjc.2017.276. Epub 2017 Aug 29.

37.

ERK1 is dispensable for mouse pancreatic beta cell function but is necessary for glucose-induced full activation of MSK1 and CREB.

Leduc M, Richard J, Costes S, Muller D, Varrault A, Compan V, Mathieu J, Tanti JF, Pagès G, Pouyssegur J, Bertrand G, Dalle S, Ravier MA.

Diabetologia. 2017 Oct;60(10):1999-2010. doi: 10.1007/s00125-017-4356-6. Epub 2017 Jul 18.

PMID:
28721437
38.

Validation of commercial ERK antibodies against the ERK orthologue of the scleractinian coral Stylophora pistillata.

Courtial L, Picco V, Pagès G, Ferrier-Pagès C.

Version 2. F1000Res. 2017 Apr 26 [revised 2017 Jan 1];6:577. doi: 10.12688/f1000research.11365.2. eCollection 2017.

39.

Effects of proton versus photon irradiation on (lymph)angiogenic, inflammatory, proliferative and anti-tumor immune responses in head and neck squamous cell carcinoma.

Lupu-Plesu M, Claren A, Martial S, N'Diaye PD, Lebrigand K, Pons N, Ambrosetti D, Peyrottes I, Feuillade J, Hérault J, Dufies M, Doyen J, Pagès G.

Oncogenesis. 2017 Jul 3;6(7):e354. doi: 10.1038/oncsis.2017.56.

40.

Extracellular Signal-Regulated Kinase Signaling in CD4-Expressing Cells Inhibits Osteochondromas.

Wehenkel M, Corr M, Guy CS, Edwards BA, Castellaw AH, Calabrese C, Pagès G, Pouysségur J, Vogel P, McGargill MA.

Front Immunol. 2017 May 1;8:482. doi: 10.3389/fimmu.2017.00482. eCollection 2017.

41.

Targeted therapies in breast cancer: New challenges to fight against resistance.

Masoud V, Pagès G.

World J Clin Oncol. 2017 Apr 10;8(2):120-134. doi: 10.5306/wjco.v8.i2.120. Review.

42.

The c-Jun N-terminal kinase prevents oxidative stress induced by UV and thermal stresses in corals and human cells.

Courtial L, Picco V, Grover R, Cormerais Y, Rottier C, Labbe A, Pagès G, Ferrier-Pagès C.

Sci Rep. 2017 Apr 4;7:45713. doi: 10.1038/srep45713.

43.

Synthesis and anti-cancer activities of new sulfonamides 4-substituted-triazolyl nucleosides.

Alaoui S, Dufies M, Driowya M, Demange L, Bougrin K, Robert G, Auberger P, Pagès G, Benhida R.

Bioorg Med Chem Lett. 2017 May 1;27(9):1989-1992. doi: 10.1016/j.bmcl.2017.03.018. Epub 2017 Mar 9.

PMID:
28325600
44.

Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas.

Dufies M, Giuliano S, Ambrosetti D, Claren A, Ndiaye PD, Mastri M, Moghrabi W, Cooley LS, Ettaiche M, Chamorey E, Parola J, Vial V, Lupu-Plesu M, Bernhard JC, Ravaud A, Borchiellini D, Ferrero JM, Bikfalvi A, Ebos JM, Khabar KS, Grépin R, Pagès G.

Cancer Res. 2017 Mar 1;77(5):1212-1226. doi: 10.1158/0008-5472.CAN-16-3088. Epub 2017 Jan 13.

45.

Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies.

Guyot M, Hilmi C, Ambrosetti D, Merlano M, Lo Nigro C, Durivault J, Grépin R, Pagès G.

Oncotarget. 2017 Feb 7;8(6):9174-9188. doi: 10.18632/oncotarget.13942.

46.

mGlu5 receptor antagonist blocks bromocriptine-induced conditioned place preference in bilateral mesolimbic-lesioned rat.

Ouachikh O, Chassain C, Pagès G, Durif F, Hafidi A.

Behav Brain Res. 2017 Jan 15;317:301-310. doi: 10.1016/j.bbr.2016.09.030. Epub 2016 Sep 13.

PMID:
27638036
47.

ERK1/2/MAPK pathway-dependent regulation of the telomeric factor TRF2.

Picco V, Coste I, Giraud-Panis MJ, Renno T, Gilson E, Pagès G.

Oncotarget. 2016 Jul 19;7(29):46615-46627. doi: 10.18632/oncotarget.10316.

48.

Telomeric repeat-binding factor 2: a marker for survival and anti-EGFR efficacy in oral carcinoma.

Benhamou Y, Picco V, Raybaud H, Sudaka A, Chamorey E, Brolih S, Monteverde M, Merlano M, Lo Nigro C, Ambrosetti D, Pagès G.

Oncotarget. 2016 Jul 12;7(28):44236-44251. doi: 10.18632/oncotarget.10005.

49.

ERK1 as a Therapeutic Target for Dendritic Cell Vaccination against High-Grade Gliomas.

Ku MC, Edes I, Bendix I, Pohlmann A, Waiczies H, Prozorovski T, Günther M, Martin C, Pagès G, Wolf SA, Kettenmann H, Uckert W, Niendorf T, Waiczies S.

Mol Cancer Ther. 2016 Aug;15(8):1975-87. doi: 10.1158/1535-7163.MCT-15-0850. Epub 2016 Jun 2.

50.

The telomere proteins in tumorigenesis and clinical outcomes of oral squamous cell carcinoma.

Benhamou Y, Picco V, Pagès G.

Oral Oncol. 2016 Jun;57:46-53. doi: 10.1016/j.oraloncology.2016.04.006. Epub 2016 Apr 28. Review.

PMID:
27208844

Supplemental Content

Support Center